Outsourcing

Articles

AGC Biologics is expanding manufacturing capacity at its Heidelberg, Germany, facility for plasmid DNA and messenger RNA.

AGC Bio Boosts Manufacturing Capacity for pDNA and mRNA at Heidelberg Facility

AGC Biologics has broken ground on a new multipurpose facility in Copenhagen, Denmark, that will increase capacity.

AGC Biologics Breaks Ground on New Multipurpose Facility in Denmark

Lonza plans to establish drug product manufacturing capabilities at is site in Guangzhou, China, to produce clinical trial and commercial supply in the country.

Lonza Invests in Drug Product Manufacturing Services in China

Craig A. Steger is SVP–Life Sciences at Outcome Capital LLC, 99 High St., Suite 2900, Boston MA.

Thomas J. Joyce is Associate at Outcome Capital LLC, 99 High St., Suite 2900, Boston MA.

Oded Ben-Joseph, PhD, is Managing Director, at Outcome Capital LLC, 99 High St., Suite 2900, Boston MA.

The CRO market will see greater consolidation by both financial buyers looking to consolidate smaller players and larger CRO players wanting to expand into value-added specialty service areas.

Pharma Services Sector Poised for Continued Growth and Consolidation

The extended manufacturing agreement between Pinteon and Lonza enables future clinical production of PNT001, a novel Tau antibody therapeutic that targets Alzheimer's disease and traumatic brain injury.

Pinteon and Lonza Extend Collaboration for Manufacturing Antibody Therapeutic

Selexis and KBI Biopharma will use integrated services to advance Immatics’ TCR bispecifics drug development program to the IND stage.

Selexis and KBI Biopharma Partner with Immatics to Advance T-Cell Bispecific Program

The companies will utilize the Cocoon Platform for clinical point-of-care manufacturing.

Lonza and CellPoint Collaborate to Develop T-cell Based Therapies

VIVEbiotech has opened its new lentiviral vector manufacturing facilities in Spain, expanding capacity for lentiviral vectors for use in cell and gene therapies.

VIVEbiotech Launches Lentiviral Vector Manufacturing Plant for Cell and Gene Therapies

AGC Biologics has partnered with BioNTech to further supply plasmid DNA starting material from its Heidelberg, Germany, facility for the Pfizer-BioNTech COVID-19 vaccine.

AGC Biologics to Supply More Plasmid DNA for Pfizer-BioNTech COVID-19 Vaccine

Feliza Mirasol is the science editor for 

The expected growth of the global bio/pharmaceutical market is pushing for the continued evolution of the CDMO arena.

Contract Manufacturing, Biopharmaceutical Production